Content
Today's DailyTalk
Article By:
TalkMarkets DailyTalk
Read
Thursday, October 31, 2013 3:59 PM EDT
Here's what we're reading. It's all good.
In this article: DNDN, GOOG, ORCL, RHT NOW IBM
The Case For Shorting Myriad Genetics
Article By:
Ketan Desai
Read
Friday, October 4, 2013 11:00 AM EDT
Many articles have been written about Myriad Genetics (MYGN) – some bullish, some bearish. This is a bearish article, looking at the company from a different angle.
In this article: MYGN
The Company You Keep Speaks Volumes: Novabay And Trius
Article By:
John Eastman
Read
Thursday, October 3, 2013 4:18 PM EDT
The great potential of a drug or remedy that may make it a significant seller and revenue driver for years to come is one thing. But the partners and interested parties early on suggests a depth that a long term stakeholder should pay attention to.
Medical Marijuana (MJNA) Rises To The Top Of Pot Stocks
Article By:
Elite E Services
Read
Monday, January 14, 2013 2:39 PM EDT
We've been monitoring the situation with Marijuana legalization since a series of announcements by states such as Colorado legalizing Marijuana for medical and eventual recreational use.
New Use For Paxil Could Mean Potential Blockbuster For GlaxoSmithKline
Article By:
Vivian Lewis
Read
Wednesday, December 19, 2012 6:00 AM EDT
GlaxoSmithKline's well known drug for depression, Paxil, is found to be successful in treating diabetes. A new use for an old drug could mean massive profits for GSK.
In this article: GSK
